Therapy Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Carboplatin + Ivonescimab + Pemetrexed Disodium + RMC-6291
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Carboplatin Paraplatin CBDCA Chemotherapy - Platinum 7 Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).
Ivonescimab AK112|AK 112|AK-112|SMT112|SMT 112|SMT-112 Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 136 VEGFA Antibody 5 Ivonescimab is a bispecific antibody that binds PD-1 and VEGFA, potentially resulting in antitumor activity (PMID: 37593227).
Pemetrexed Disodium Alimta LY231514|Ciambra|pemetrexed Chemotherapy - Antimetabolite 14 Alimta (pemetrexed disodium) is an antifolate that inhibits thymidylate synthase (NCI Drug Dictionary).
RMC-6291 RMC6291RM032|RM-032|RMC 6291 KRAS G12C inhibitor 36 RMC-6291 is a small molecule that selectively inhibits active KRAS G12C by forming a tri-complex with KRAS G12C and cyclophilin A, potentially resulting in decreased RAS signaling and tumor cell proliferation, and reduced tumor growth (PMID: 37590355).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT07397338 Phase Ib/II Ivonescimab + RMC-9805 Cetuximab + Ivonescimab + RMC-9805 Ivonescimab + RMC-6291 Daraxonrasib + Ivonescimab + RMC-6291 Carboplatin + Ivonescimab + Pemetrexed Disodium + RMC-6291 Cisplatin + Ivonescimab + Pemetrexed Disodium + RMC-6291 Daraxonrasib + Ivonescimab Carboplatin + Daraxonrasib + Ivonescimab + Pemetrexed Disodium Cisplatin + Daraxonrasib + Ivonescimab + Pemetrexed Disodium Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors Recruiting USA 0


Additional content available in Icon for CKB-BoostCKB BOOST